Creative Medical Technology Holdings, Inc. (CELZ)
(Delayed Data from NSDQ)
$3.57 USD
-0.24 (-6.28%)
Updated Jul 8, 2024 03:50 PM ET
After-Market: $3.66 +0.09 (2.52%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CELZ 3.57 -0.24(-6.28%)
Will CELZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CELZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CELZ
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
CELZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Other News for CELZ
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelzĀ® ProgramĀ with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
Creative Medical Technology announces development of IPSCelz program
CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024